EXACT SCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.08 USD | +1.10% |
|
+4.10% | -26.90% |
| May. 23 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
| May. 21 | Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed | MT |
Chart calendar Exact Sciences Corporation
b56ad97.Ro4tFZts7gXDF2wr58Y_wbAnJcLLDYrM4p7ZtfJVgww.NdhcW8wmtzWBViFskf8KsdsfbYCSWO6Tk9yA24c0zGsh-2tM0RuFQK9DJQ~c6b3d194225d89b0d93a0b01451cb241
Upcoming events on Exact Sciences Corporation
Past events on Exact Sciences Corporation
| 2024-05-20 | Benchmark Healthcare House Virtual Conference |
| 2024-05-18 12:30 pm | Digestive Disease Week Conference |
| 2024-05-15 04:40 pm | BofA Securities Health Care Conference |
| 2024-05-08 05:00 pm | Q1 2024 Earnings Call |
| 2024-05-08 04:05 pm | Q1 2024 Earnings Release |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Poster Number: LB100/11 |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Poster Number: 2449/14 |
| 2024-03-14 08:00 am | Cologuard Plus™ BLUE-C Study Results Call |
| 2024-03-04 01:30 pm | TD Cowen Health Care Conference |
| 2024-02-21 05:00 pm | Q4 2023 Earnings Call |
| 2024-02-21 04:05 pm | Q4 2023 Earnings Release |
| 2024-01-08 02:15 pm | JPMorgan Healthcare Conference |
| 2023-12-08 01:00 pm | San Antonio Breast Cancer Symposium - Poster ID PO5-13-05 |
| 2023-12-08 01:00 pm | San Antonio Breast Cancer Symposium - LBO1-05 |
| 2023-12-08 01:00 pm | San Antonio Breast Cancer Symposium - Presentation ID: PO5-02-04 |
| 2023-12-08 01:00 pm | San Antonio Breast Cancer Symposium - Poster ID P05-13-06 |
| 2023-12-08 09:15 am | San Antonio Breast Cancer Symposium - GS03-01 |
| 2023-12-07 06:00 pm | San Antonio Breast Cancer Symposium - PO4-08-09 |
| 2023-12-07 05:00 pm | San Antonio Breast Cancer Symposium |
| 2023-12-06 06:00 pm | San Antonio Breast Cancer Symposium - Poster ID PO2-06-10 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 876 878 -0.22% | 1 491 1 472 1.3% | 1 767 1 744 1.33% | 2 084 2 073 0.53% | 2 500 2 492 0.31% | 2 830 |
|
EBITDA Million USD | Released Forecast Spread | -121 -147 17.7% | 26,1 -32,3 180.84% | -188 -388 51.54% | -143 -205 30.04% | 219 203 7.66% | 331 |
|
EBIT Million USD | Released Forecast Spread | -171 -179 4.25% | -137 -221 37.92% | -599 -691 13.3% | -580 -577 -0.45% | -259 -242 -6.86% | -189 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -269 -212 -27.03% | -857 -427 -100.93% | -843 -763 -10.42% | -633 -642 1.49% | -202 -246 17.98% | -183 |
|
Net income Million USD | Released Forecast Spread | -84,0 -211 60.28% | -849 -391 -116.93% | -596 -517 -15.19% | -624 -630 1.1% | -204 -259 21.22% | -196 |
|
EPS USD | Released Forecast Spread | -0,64 -1,61 60.16% | -5,61 -2,71 -107.29% | -3,48 -3,03 -15.01% | -3,54 -3,57 0.95% | -1,13 -1,43 20.84% | -1,05 |
| Announcement Date | 11/02/20 | 16/02/21 | 22/02/22 | 21/02/23 | 21/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 487 460 5.76% | 522 496 5.14% | 523 503 3.97% | 553 526 5.21% | 602 543 10.91% | 622 601 3.49% | 628 617 1.83% | 647 640 1.12% | 638 627 1.71% | 692 | 731 | 772 | 732 | 791 |
|
EBITDA Million USD | Released Forecast Spread | -89,8 -126 28.5% | -45,8 -92,3 50.43% | -13,0 -95,5 86.35% | 4,93 -49,3 110.02% | 45,9 -14,6 413.57% | 66,9 25,6 160.89% | 56,3 34,7 62.09% | 49,7 37,7 31.74% | 39,2 30,3 29.48% | 70,4 | 103 | 122 | 80,8 | 121 |
|
EBIT Million USD | Released Forecast Spread | -203 -184 -10.04% | -162 -184 12.02% | -120 -184 34.88% | -95,3 -136 29.89% | -65,7 -127 48.17% | -72,1 -96,1 24.97% | -68,1 -88,0 22.64% | -70,9 -70,8 -0.22% | -88,3 -95,2 7.27% | -57,5 | -24,1 | -8,16 | -49,5 | -11,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -183 -193 5.22% | -168 -196 14.48% | -152 -195 22.06% | -130 -153 14.96% | -72,5 -138 47.46% | -79,9 -92,9 14% | 1,04 -92,3 101.13% | -50,4 -85,6 41.12% | -108 -94,0 -15.28% | -56,8 | -22,4 | -8,55 | -49,9 | -11,0 |
|
Net income Million USD | Released Forecast Spread | -181 -190 4.82% | -166 -195 15% | -149 -195 23.65% | -128 -153 16.62% | -74,2 -141 47.44% | -81,0 -90,8 10.8% | 0,79 -86,9 100.91% | -49,8 -92,3 46.09% | -110 -89,1 -23.7% | -58,4 | -25,8 | -8,29 | -51,2 | -14,9 |
|
EPS USD | Released Forecast Spread | -1,04 -1,14 8.37% | -0,94 -1,08 12.89% | -0,84 -1,07 21.72% | -0,72 -0,83 13.43% | -0,42 -0,77 45.41% | -0,45 -0,51 11.33% | 0,00 -0,48 - | -0,27 -0,48 43.95% | -0,60 -0,49 -21.97% | -0,31 | -0,13 | -0,04 | -0,24 | -0,05 |
| Announcement Date | 26/04/22 | 02/08/22 | 03/11/22 | 21/02/23 | 09/05/23 | 01/08/23 | 01/11/23 | 21/02/24 | 08/05/24 | - | - | - | - | - |
More events
Past sector events for Exact Sciences Corporation
| 2024-05-09 | SEEGENE, INC.: Q1 2024 Earnings Release |
| 2024-05-09 04:05 pm | GUARDANT HEALTH, INC.: Q1 2024 Earnings Release |
| 2024-05-09 04:01 pm | IOVANCE BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-08 04:05 pm | MARAVAI LIFESCIENCES HOLDINGS, INC.: Q1 2024 Earnings Release |
| 2024-05-08 04:05 pm | EXACT SCIENCES CORPORATION: Q1 2024 Earnings Release |
| 2024-05-07 04:05 pm | VERACYTE, INC.: Q1 2024 Earnings Release |
| 2024-04-26 | BGI GENOMICS CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-12 | BGI GENOMICS CO., LTD.: Q4 2023 Earnings Release |
| 2024-02-28 04:05 pm | CAREDX, INC: Q4 2023 Earnings Release |
| 2024-02-28 04:01 pm | IOVANCE BIOTHERAPEUTICS, INC.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- EXAS Stock
- Calendar Exact Sciences Corporation
